FDA Grants Orphan Drug Designation to lfetroban for Treatment of Duchenne Muscular Dystrophy-Associated Cardiomyopathy

News I Article I November 8, 2024 FDA Grants Orphan Drug Designation to lfetroban for Treatment of Duchenne Muscular Dystrophy-Associated Cardiomyopathy Author(s): Luke Halriern, .. AssistaruJ:.QL\:gr oeoee Listen 0:00 / 4:44 Key Takeaways • lfetroban received FDA orphan drug and rare pediatric disease designations for cardiomyopathy in Duchenne muscular dystrophy. • The FIGHT DMD trial evaluates ifetroban's effectiveness, safety, and pharmacokinetics in DMD patients. SHOW MORE The drug is being investigated for its potential to reduce fibrosis associated with muscular dystrophy that con cause scarring of the heart tissue. The FDA granted orphan drug designation (ODD) and rare pediatric disease (RPD) designation to ifetroban, a thromboxane-prostanoid receptor (TPr) antagonist, for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD), according to a news release from Cumberland Pharmaceuticals.1 "For Duchenne muscular dystrophy, a devastating genetic disorder affecting young boys, securing both orphan drug and rare pediatric disease designations for ifetroban from the FDA is a critical step forward," AJ Kazimi, CEO of Cumberland Duchenne muscular dysrroplly can cause skeletal and musclt weakness. I Image Credit: tel Premium Graphics I stock.adobe com Pharmaceuticals, said in the news release.1 ODD is granted by the FDA to encourage the development of new therapies for rare diseases or conditions through clinical

The release as fetched from its publisher. cumberlandpharma.com ↗